The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants

Structure and function of serotonin G protein-coupled receptors

(2015) John D. McCorvy et al.   PHARMACOLOGY & THERAPEUTICS

Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data

(2015) Connie Sanchez et al.   PHARMACOLOGY & THERAPEUTICS

Positron Emission Tomography Quantification of Serotonin1AReceptor Binding in Suicide Attempters With Major Depressive Disorder

(2015) Gregory M. Sullivan et al.   JAMA Psychiatry

Of mice and men: modelling post-stroke depression experimentally

(2014) G Kronenberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder

(2014) Lesley J. Scott   CNS DRUGS

Modulating the serotonin system in the treatment of major depressive disorder

(2014) Debbi Ann Morrissette et al.   CNS SPECTRUMS

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

(2014) William James Deardorff et al.   EXPERT OPINION ON PHARMACOTHERAPY

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

(2014) Roger S. McIntyre et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus

(2014) Elena Dale et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Levomilnacipran: a newly approved drug for treatment of major depressive disorder

(2014) Rajnish Mago et al.   Expert Review of Clinical Pharmacology

Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

(2013) A. Shin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Improving the Treatment of Schizophrenia: Role of 5-HT Receptors in Modulating Cognitive and Extrapyramidal Motor Functions

(2013) Saki Shimizu et al.   CNS & Neurological Disorders-Drug Targets

Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

(2013) Pau Celada et al.   CNS DRUGS

Serotonergic Drugs for Depression and Beyond

(2013) Stephen M. Stahl et al.   CURRENT DRUG TARGETS

Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review

(2013) Merce Masana et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

A proposal for an updated neuropsychopharmacological nomenclature

(2013) Joseph Zohar et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Differenzialindikation von Antidepressiva

(2013) S. Köhler et al.   FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE

Vilazodone in the treatment of major depressive disorder

(2013) Arif Khan et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2013) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets

(2013) Gary M. Mawe et al.   Nature Reviews Gastroenterology & Hepatology

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

(2013) A.L. Auclair et al.   NEUROPHARMACOLOGY

Serotonin 1A receptors and sexual behavior in male rats: A review

(2013) Eelke M.S. Snoeren et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Rediscovering Trazodone for the Treatment of Major Depressive Disorder

(2012) Andrea Fagiolini et al.   CNS DRUGS

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

(2012) David S. Baldwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2012) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder

(2012) Jenifer A. Murphy et al.   JOURNAL OF AFFECTIVE DISORDERS

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

(2012) Jean-Philippe Boulenger et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder

(2012) Anita H. Clayton et al.   Journal of Sexual Medicine

Neuroreceptor imaging in depression

(2012) Jonathan B. Savitz et al.   NEUROBIOLOGY OF DISEASE

Vilazodone for the Treatment of Major Depressive Disorder

(2012) Maryam Iranikhah et al.   PHARMACOTHERAPY

Preclinical and clinical characterization of the selective 5-HT1Areceptor antagonist DU-125530 for antidepressant treatment

(2011) MC Scorza et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Roles of Neurotrophic Factor and Wnt Signaling in Depression

(2011) B Voleti et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways

(2011) Rebeca Vidal et al.   CURRENT PHARMACEUTICAL DESIGN

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited

(2011) Jolanda Prins et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The 5-HT7 receptor in learning and memory

(2011) Amanda J. Roberts et al.   HIPPOCAMPUS

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Triptans for the Management of Migraine

(2010) Mollie M. Johnston et al.   DRUGS

Review: The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?

(2010) Ramamoorthy Rajkumar et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

(2010) Mike Briley   Neuropsychiatric Disease and Treatment

The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression (Supplementary Tables)

(2009) B. Ruf et al.   CURRENT DRUG TARGETS

Antagonism of serotonergic 5-HT2A/2Creceptors: mutual improvement of sleep, cognition and mood?

(2009) H.-P. Landolt et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics

(2009) David C. Henderson   JOURNAL OF CLINICAL PSYCHIATRY

The CRF system, stress, depression and anxiety—insights from human genetic studies

(2009) E B Binder et al.   MOLECULAR PSYCHIATRY

Elevated Serotonin 1A Binding in Remitted Major Depressive Disorder: Evidence for a Trait Biological Abnormality

(2009) Jeffrey M Miller et al.   NEUROPSYCHOPHARMACOLOGY

The 5-HT7 receptor and disorders of the nervous system: an overview

(2009) Peter B. Hedlund   PSYCHOPHARMACOLOGY

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran

(2008) David Baldwin et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Comment on: ‘Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence’

(2008) Thomas A. Ban   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat

(2008) Alice Egerton et al.   PSYCHOPHARMACOLOGY

Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons

(2007) Gary A. Gudelsky et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR